Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.5
Journals
Metabolites
Special Issues
Lipid Metabolism in Age-Related Diseases
share announcement

Lipid Metabolism in Age-Related Diseases

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Lipid Metabolism".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 2030

Special Issue Editors

Dr. Simona Fenizia

E-Mail Website
Guest Editor
Department of Sciences and Technological Innovation, University of Piemonte Orientale, Corso Trieste 15/A, I-28100 Novara, Italy
Interests: analytical chemistry; metabolomics; lipidomics; biomarker discovery; chromatography; mass spectrometry
Dr. Elettra Barberis

E-Mail Website
Guest Editor
Department of Sciences and Technological Innovation, University of Piemonte Orientale, Corso Trieste 15/A, I-28100 Novara, Italy
Interests: analytical chemistry; metabolomics; lipidomics; biomarker discovery; chromatography; mass spectrometry
Special Issues, Collections and Topics in MDPI journals
Dr. Marcello Manfredi

E-Mail Website
Guest Editor
Department of Translational Medicine (DiMeT), Center for Translational Research on Autoimmune & Allergic Diseases—CAAD, University of Piemonte Orientale, Corso Trieste 15/A, 28100 Novara, Italy
Interests: cancer and microenvironment; biochemistry; mass spectrometry based-omics analysis; tumour microenvironment; biomarkers; aging related diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Lipids play an important role in the development of aging-related diseases. Alteration of lipid metabolism has already been identified in both chronic and acute diseases, including cardiovascular, metabolic, cancer, autoimmune, and neurodegenerative diseases. In addition, impaired lipid metabolism is implicated in all the known hallmarks of aging. A growing body of literature shows that specific lipid subclasses and species can serve as biomarkers and targets for therapies, paving the way for the development of precision medicine approaches. Although lipids are involved in many cellular and physiological regulations, their heterogeneity and wide dynamic range make the study of these molecules very challenging. Mass spectrometry and chromatography have been largely developed in recent years, leading to significant advances in the exploration and analysis of human lipid profiles. This Special Issue aims to explore the contribution of lipid biosynthesis, accumulation, and metabolism in the context of aging-related diseases. Submissions from basic research and clinical studies, including the development and application of analytical methods to investigate the role of lipids in both chronic and acute diseases, are welcome. Furthermore, we aim to present cutting-edge reviews and original research articles that investigate the role of lipid metabolism both in vivo and in vitro, as well as biomarker discovery, analytical challenges in lipidomic research, and future perspectives on targeting lipid pathways to improve therapeutic strategies.

Our Special Issue welcomes researchers, scientists, and experts from different fields, including metabolomics, biochemistry, and clinical medicine, to contribute original research articles, reviews, and insights investigating the intricate mechanisms linking lipid alterations in age-related diseases.

We also encourage submissions that explore novel diagnostic biomarkers, therapeutic interventions, and preventive strategies.

Key topics of interest include the following:

- Investigation of lipid metabolism in vitro and in vivo;
- Discovery of new lipid biomarkers;
- Role of lipids in aging diseases;
- Current and future perspectives on lipids in diseases and the elderly;
- Advanced methods for the analysis of lipids and fatty acids in biological fluids and in vitro models.

Dr. Simona Fenizia
Dr. Elettra Barberis
Dr. Marcello Manfredi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lipid metabolism
  • metabolic diseases
  • high-throughput mass spectrometry-based lipidomics
  • aging
  • lipid biomarkers
  • precision medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 717 KiB  
Article
Differences in the Prevalence and Clinical Correlates Between Early-Onset and Late-Onset Major Depressive Disorder Patients with Comorbid Abnormal Lipid Metabolism
by Xiao Huang, Anshi Wu and Xiangyang Zhang
Metabolites 2025, 15(2), 117; https://doi.org/10.3390/metabo15020117 - 11 Feb 2025
Viewed by 663
Abstract
Background and Objectives: Growing evidence suggested that abnormal lipid metabolism (ALM) was associated with an increased severity of depressive symptoms, but no previous studies have examined the differences in comorbid ALM in major depressive disorder (MDD) patients of different ages of onset. We [...] Read more.
Background and Objectives: Growing evidence suggested that abnormal lipid metabolism (ALM) was associated with an increased severity of depressive symptoms, but no previous studies have examined the differences in comorbid ALM in major depressive disorder (MDD) patients of different ages of onset. We aim to compare the differences in the prevalence and clinical correlates of ALM between early-onset and late-onset patients with first-episode and drug-naive (FEDN) MDD patients. Methods: Using a cross-sectional design, we recruited a total of 1718 FEDN MDD outpatients in this study. We used the 17-item Hamilton Rating Scale for Depression (HAMD-17), The Hamilton Anxiety Rating Scale (HAMA), the Positive and Negative Syndrome Scale (PANSS) positive subscale, and Clinical Global Impression-Severity Scale (CGI-S) to assess their depression, anxiety, and psychotic symptoms and clinical severity, respectively. Results: There were 349 patients (20.3%) in the early-onset subgroup and 1369 (79.7%) in the late-onset subgroup. In this study, 65.1% (1188/1718) of patients were diagnosed with ALM. The prevalence of ALM in the late-onset group (81.5%, 1116/1369) was significantly higher than that in the early-onset group (20.6%, 72/349) (p = 0.36, OR = 1.147, 95%CI = 0.855–1.537). The HAMD total score (OR = 1.34, 95% CI = 1.18–1.53, p < 0.001) was the only risk factor for ALM in early-onset MDD patients. In late-onset MDD patients, the HAMD total score (OR = 1.19, 95% CI = 1.11–1.28, p < 0.001), TSH (OR = 1.25, 95% CI = 1.16–1.36, p < 0.001), CGI (OR = 1.7, 95% CI = 1.31–2.19, p < 0.001), and anxiety (OR = 2.22, 95% CI = 1.23–4.02, p = 0.008) were risk factors for ALM. Conclusion and Scientific Significance: Our results suggest that there are significant differences in the prevalence and clinical factors of comorbid ALM between early-onset and late-onset FEND MDD patients. Full article
(This article belongs to the Special Issue Lipid Metabolism in Age-Related Diseases)
►▼ Show Figures

Figure 1

Review

Jump to: Research

27 pages, 788 KiB  
Review
Lipid Metabolism and Statin Therapy in Neurodegenerative Diseases: An Endocrine View
by Antonella Di Sarno, Fiammetta Romano, Rossana Arianna, Domenico Serpico, Mariarosaria Lavorgna, Silvia Savastano, Annamaria Colao and Carolina Di Somma
Metabolites 2025, 15(4), 282; https://doi.org/10.3390/metabo15040282 - 18 Apr 2025
Viewed by 340
Abstract
Background/aim: A growing body of evidence suggests a link between dyslipidemias and neurodegenerative diseases, highlighting the crucial role of lipid metabolism in the health of the central nervous system. The aim of our work was to provide an update on this topic, [...] Read more.
Background/aim: A growing body of evidence suggests a link between dyslipidemias and neurodegenerative diseases, highlighting the crucial role of lipid metabolism in the health of the central nervous system. The aim of our work was to provide an update on this topic, with a focus on clinical practice from an endocrinological point of view. Endocrinologists, being experts in the management of dyslipidemias, can play a key role in the prevention and treatment of neurodegenerative conditions, through precocious and effective lipid profile optimization. Methods: The literature was scanned to identify clinical trials and correlation studies on the association between dyslipidemia, statin therapy, and the following neurodegenerative diseases: Alzheimer’s disease (AD), Parkisons’s disease (PD), Multiple sclerosis (MS), and Amyotrophic lateral sclerosis (ALS). Results: Impaired lipid homeostasis, such as that frequently observed in patients affected by obesity and diabetes, is related to neurodegenerative diseases, such as AD, PD, and other cognitive deficits related to aging. AD and related dementias are now a real priority health problem. In the United States, there are approximately 7 million subjects aged 65 and older living with AD and related dementias, and this number is projected to grow to 12 million in the coming decades. Lipid-lowering therapy with statins is an effective strategy in reducing serum low-density lipoprotein cholesterol to normal range concentrations and, therefore, cardiovascular disease risk; moreover, statins have been reported to have a positive effect on neurodegenerative diseases. Conclusions: Several pieces of research have found inconsistent information following our review. There was no association between statin use and ALS incidence. More positive evidence has emerged regarding statin use and AD/PD. However, further large-scale prospective randomized control trials are required to properly understand this issue. Full article
(This article belongs to the Special Issue Lipid Metabolism in Age-Related Diseases)
►▼ Show Figures

Figure 1

19 pages, 1503 KiB  
Review
Ceramide in Coronary Artery Disease: Troublesome or Helpful Future Tools in the Assessment of Risk Prediction and Therapy Effectiveness?
by Melania Gaggini, Adrian Florentin Suman and Cristina Vassalle
Metabolites 2025, 15(3), 168; https://doi.org/10.3390/metabo15030168 - 1 Mar 2025
Viewed by 654
Abstract
Lipids are a complex entity of different molecules, among which ceramides (Cers), ubiquitous sphingolipids with remarkable biological activity, can represent a potential additive biomarker that can be used to better understand the underlying mechanisms which drive the onset and development of atherosclerotic damage [...] Read more.
Lipids are a complex entity of different molecules, among which ceramides (Cers), ubiquitous sphingolipids with remarkable biological activity, can represent a potential additive biomarker that can be used to better understand the underlying mechanisms which drive the onset and development of atherosclerotic damage and plaque vulnerability and facilitate coronary disease management, as possible risk/prognostic biomarkers and targets for therapeutic intervention. Accordingly, this review aims to discuss the available results on the role Cersplay in contributing to atherosclerosis development and acute coronary event precipitation, their impact on complications and adverse prognosis, as well as the impact of treatment options in modulating Cerlevels. Full article
(This article belongs to the Special Issue Lipid Metabolism in Age-Related Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop